US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kairos Acquisition Corp.

10.08

+0.0000

Volume:- -

Turnover:- -

Market Cap:347.59M

PE:26.48

High:10.08

Open:10.08

Low:10.08

Close:10.08

Loading ...

Overview Company News Filings

Kairos Minerals Targets Resource Growth at Mt York Gold Project

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Minerals Transitions Share Registry Services to Xcend

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma

Resources Top 5: Cashed-up Kairos positioned to progress Mt York gold project

Kairos Minerals’ Mt York Project Scoping Study Reveals Strong Financial Prospects

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Aurelia Metals Finds 'Significant' Copper, Gold in New South Wales Deposits

MT Newswires Live

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma Ltd trading halted, news pending

Kairos Minerals Announces Issuance of Performance Rights

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Japan's Space One Kairos rocket fails minutes after liftoff

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Kairos Minerals Director Acquires 85M Performance Rights

Environmental Group And 2 Other ASX Penny Stocks To Boost Your Portfolio

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KAIR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KAIR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAIR\",,,,,undefined,":{"symbol":"KAIR","market":"US","secType":"STK","nameCN":"Kairos Acquisition Corp.","latestPrice":10.075,"timestamp":1688155200000,"preClose":10.075,"halted":0,"volume":0,"delay":0,"floatShares":19423255,"shares":34500000,"eps":0.380483,"marketStatus":"Market Closed","change":0,"latestTime":"06-30 16:00:00 EDT","open":10.075,"high":10.075,"low":10.075,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.380483,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":10.075,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAIR\",,,,,undefined,":{"symbol":"KAIR","floatShares":19423255,"roa":"-0.96%","roe":"--","lyrEps":0.243197,"shares":34500000,"dividePrice":0,"high":10.075,"amplitude":0,"preClose":10.075,"low":10.075,"week52Low":9.705,"pbRate":"-33.11","week52High":10.08,"institutionHeld":0,"latestPrice":10.075,"eps":0.380483,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.380483,"open":10.075,"prevYearClose":10.075},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAIR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514075969","title":"Kairos Minerals Targets Resource Growth at Mt York Gold Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2514075969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514075969?lang=en_us&edition=fundamental","pubTime":"2025-02-26 10:48","pubTimestamp":1740538107,"startTime":"0","endTime":"0","summary":"An announcement from Kairos Minerals ( ($AU:KAI) ) is now available. Kairos Minerals has announced plans to advance its Mt York Gold Project, with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-targets-resource-growth-at-mt-york-gold-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-targets-resource-growth-at-mt-york-gold-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4109","MTX","KAIR"],"gpt_icon":0},{"id":"2512195122","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512195122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512195122?lang=en_us&edition=fundamental","pubTime":"2025-02-19 02:48","pubTimestamp":1739904480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 13:48 ET (18:48 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2512840150","title":"Kairos Pharma Announces New Department of Defense Funding for Research of ENV205","url":"https://stock-news.laohu8.com/highlight/detail?id=2512840150","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512840150?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:30","pubTimestamp":1739885400,"startTime":"0","endTime":"0","summary":"LOS ANGELES, February 18, 2025----Kairos Pharma, Ltd. , a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205, a groundbreaking new drug to treat chemotherapy drug resistance and cachexia.This funding will accelerate the Company’s research efforts to develop ENV205, a first-in-class therapy designed to reverse chemotherapy drug resistance, counteract muscle loss, improve strength, and enhance the effectiveness of existing cancer treatments. By targeting key pathways that drive cachexia, Kairos seeks to develop ENV205 to provide a much-needed solution to help patients maintain their health and resilience throughout cancer therapy. The Company has long been partnering with Cedars-Sinai in its research and development of ENV205.Neil Bhowmick, Kairos Pharma’s Chief Scientific Of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-announces-department-defense-133000661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KAPA","KAIR","BK4139"],"gpt_icon":0},{"id":"2511655637","title":"Kairos Minerals Transitions Share Registry Services to Xcend","url":"https://stock-news.laohu8.com/highlight/detail?id=2511655637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511655637?lang=en_us&edition=fundamental","pubTime":"2025-02-14 14:57","pubTimestamp":1739516230,"startTime":"0","endTime":"0","summary":"An update from Kairos Minerals ( ($AU:KAI) ) is now available. Kairos Minerals has announced a change in its share registry services, which will no...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-transitions-share-registry-services-to-xcend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-transitions-share-registry-services-to-xcend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","BK4109","MTX"],"gpt_icon":0},{"id":"2510371849","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371849","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371849?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:12","pubTimestamp":1739365920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2025 08:12 ET (13:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2509442276","title":"Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2509442276","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509442276?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:30","pubTimestamp":1738848600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, February 06, 2025----Kairos Pharma, Ltd. , a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor  agonist, KROS101.Based in Los Angeles, California, Kairos Pharma Ltd.  is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of stan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-oral-presentation-investigational-133000061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KAPA","KROS","BK4185","JYNT","KAIR"],"gpt_icon":0},{"id":"2507384599","title":"Resources Top 5: Cashed-up Kairos positioned to progress Mt York gold project","url":"https://stock-news.laohu8.com/highlight/detail?id=2507384599","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507384599?lang=en_us&edition=fundamental","pubTime":"2025-01-31 14:25","pubTimestamp":1738304704,"startTime":"0","endTime":"0","summary":"Kairos gains on strong cash position as it plans gold drilling at Mt York. G11’s drilling in December quarter returned significant copper-rich massive sulphide intersections. Estrella raises $3.75m through placement of shares priced at 3c","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/res5_kairos_cashed_main-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/res5_kairos_cashed_main-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/resources/resources-top-5-cashed-up-kairos-positioned-to-progress-mt-york-gold-project/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["KAIR","BK1216","LU0607220059.USD","01821","LU0149534421.HKD"],"gpt_icon":0},{"id":"2507983539","title":"Kairos Minerals’ Mt York Project Scoping Study Reveals Strong Financial Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2507983539","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507983539?lang=en_us&edition=fundamental","pubTime":"2025-01-31 09:07","pubTimestamp":1738285678,"startTime":"0","endTime":"0","summary":"Kairos Minerals ( ($AU:KAI) ) has shared an announcement. Kairos Minerals has released a promising scoping study for its Mt York Gold Project, reve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-mt-york-project-scoping-study-reveals-strong-financial-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-mt-york-project-scoping-study-reveals-strong-financial-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4109","MTX","KAIR"],"gpt_icon":0},{"id":"2506515864","title":"Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2506515864","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506515864?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:15","pubTimestamp":1738070100,"startTime":"0","endTime":"0","summary":"LOS ANGELES, January 28, 2025----Kairos Pharma Ltd. , a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii.The talk, titled, \"KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment,\" will be held on February 5, 2025 at 4:00 PM local time.The American Association for Cancer Research  and Japanese Cancer Association  offer this 13th AACR-JCA Joint Conference. This meeting series has a long tradition of bringing together outstanding researchers from the United States, Japan, and around the world to share their findings and present the latest advances in basic, translational, and clinical cancer research.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-present-short-talk-131500639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KAPA","KAIR","BK4139","KROS","BK4185","JYNT"],"gpt_icon":0},{"id":"2505747712","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2505747712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505747712?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:29","pubTimestamp":1737552540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2025 08:29 ET (13:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2505978756","title":"Aurelia Metals Finds 'Significant' Copper, Gold in New South Wales Deposits","url":"https://stock-news.laohu8.com/highlight/detail?id=2505978756","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505978756?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:59","pubTimestamp":1737511168,"startTime":"0","endTime":"0","summary":"Aurelia Metals  reported \"significant\" copper and gold in its fiscal first half underground exploration programs within the Peak Mine in New South Wales, with discoveries at Kairos, Jubilee North, New Cobar, and Hercules deposits, according to a Wednesday filing with the Australian bourse.Copper grades up to 6.4% were intersected at Kairos Deeps, with drilling indicating the deposit continues 300 meters down dip from existing mine development and remains open at depth, while drilling extended known mineralization along strike at the Jubilee deposit, the filing said.Meanwhile, drilling intersected \"strong\" copper grades down-dip at New Cobar, and confirmed high-grade mineralization in the Hercules deposit, according to the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","AMI.AU","KAIR","BK7506"],"gpt_icon":0},{"id":"2505027548","title":"Kairos Pharma Provides Business Update and Outlook into 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505027548","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505027548?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:30","pubTimestamp":1737466200,"startTime":"0","endTime":"0","summary":"LOS ANGELES, January 21, 2025----Kairos Pharma Ltd. , a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook into 2025 in a Letter to Shareholders:. The management team and Board of Directors of Kairos Pharma Ltd. are pleased to provide you with a brief update on the state of business and noteworthy milestones of 2024 and outlook into 2025. Last year was focused on building the foundation for our business based on breakthrough science and impactful therapeutics, while creating the fundamental infrastructure that facilitated our entry into the public markets.Closing of our Initial Public Offering and listing of our common stock on the NYSE American stock exchange on September 16, 2024.Agreement with PreCheck Health Services to further develop a biomarker panel to identify patients responsive to ENV105 to target cancer drug resistance in prostate and lung ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-provides-business-outlook-133000168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KAPA","KAIR"],"gpt_icon":0},{"id":"2503657973","title":"Kairos Pharma Ltd trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2503657973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503657973?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:35","pubTimestamp":1736865329,"startTime":"0","endTime":"0","summary":"09:31 EST Kairos Pharma (KAPA) Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaki...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-ltd-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-ltd-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAIR","KAPA"],"gpt_icon":0},{"id":"2503326030","title":"Kairos Minerals Announces Issuance of Performance Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2503326030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503326030?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:33","pubTimestamp":1736753609,"startTime":"0","endTime":"0","summary":"An announcement from Kairos Minerals ( ($AU:KAI) ) is now available. Kairos Minerals Limited has announced the issuance of 2,000,000 performance ri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-announces-issuance-of-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-announces-issuance-of-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4109","KAIR","MTX"],"gpt_icon":0},{"id":"2501091202","title":"Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2501091202","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501091202?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:15","pubTimestamp":1736255700,"startTime":"0","endTime":"0","summary":"The webcast will also be available for replay following the event.Based in Los Angeles, California, Kairos Pharma Ltd.  is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-present-lytham-partners-131500316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4139","KAIR","KAPA","SMMF","HCSG","BK4211"],"gpt_icon":0},{"id":"2492927427","title":"Japan's Space One Kairos rocket fails minutes after liftoff","url":"https://stock-news.laohu8.com/highlight/detail?id=2492927427","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492927427?lang=en_us&edition=fundamental","pubTime":"2024-12-18 13:51","pubTimestamp":1734501060,"startTime":"0","endTime":"0","summary":"It was the second attempt by Space One to become the country's first private firm to put a satellite into orbit, after the first try in March ended in a mid-air explosion.This time its solid-fuel Kairos rocket had been carrying five satellites, including one from the Taiwan Space Agency and others designed by Japanese students and corporate ventures.Spectators gathered near the company's coastal Spaceport Kii launch pad in Japan's western Wakayama region expressed their disappointment to television cameras.\"I'm so shocked,\" one woman said after the firm announced the failure. \"I had been hoping it would go into orbit.\". News reports showed the slim, white 18m rocket soaring far into the sky.Space One's Kairos No 2 rocket, carrying satellites, is launched from Space Port Kii in Kushimoto town, western Japan on Dec 18, 2024. . But JAXA had to delay the launch of a compact, solid-fuel Epsilon S rocket after a recent engine test resulted in a large fire.","market":"us","thumbnail":"https://onecms-res.cloudinary.com/image/upload/s--uMjx47Ks--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2024-04:reuters_1,w_0.1/f_auto,q_auto/v1/one-cms/core/2024-12-18t034927z_1_lynxmpekbh030_rtroptp_3_japan-space-kairos.jpg?itok=EScnwhiM","type":0,"news_type":0,"thumbnails":["https://onecms-res.cloudinary.com/image/upload/s--uMjx47Ks--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2024-04:reuters_1,w_0.1/f_auto,q_auto/v1/one-cms/core/2024-12-18t034927z_1_lynxmpekbh030_rtroptp_3_japan-space-kairos.jpg?itok=EScnwhiM"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/east-asia/japan-space-rocket-one-kairos-fails-liftoff-4813226","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["KAIR"],"gpt_icon":0},{"id":"2492048617","title":"Kairos Pharma to Participate in The Microcap Conference in January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492048617","media":"ACCESSWIRE","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492048617?lang=en_us&edition=fundamental","pubTime":"2024-12-17 01:15","pubTimestamp":1734369300,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma,  a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.Kairos Pharma's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-participate-microcap-conference-171500214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KAIR","KAPA","BK4139"],"gpt_icon":0},{"id":"2488910690","title":"Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488910690","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488910690?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:30","pubTimestamp":1733232600,"startTime":"0","endTime":"0","summary":"ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments.LOS ANGELES, December 03, 2024----Kairos Pharma Ltd. , a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company’s randomized trial for patients receiving either apalutamide or apalutamide+ENV105 combination therapy. The additional centers allow Kairos Pharma to test ENV105 in a broader patient population to identify blood markers that could help select patients expected to benefit most from ENV105 treatment. The trial is supported by Kairos Pharma Ltd. and a grant from the National Cancer Institute .This pre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ijWwXjgPhNVNW.SLpaS2oQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58eb5cf675810d6dd8fe6b86f3e5cc6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ijWwXjgPhNVNW.SLpaS2oQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58eb5cf675810d6dd8fe6b86f3e5cc6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-adds-city-hope-133000317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KAPA","NCI","BK4211","CHCO","BK4202","HOPE","KAIR","BK4139"],"gpt_icon":0},{"id":"2488961038","title":"Kairos Minerals Director Acquires 85M Performance Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2488961038","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488961038?lang=en_us&edition=fundamental","pubTime":"2024-12-03 15:23","pubTimestamp":1733210601,"startTime":"0","endTime":"0","summary":"Kairos Minerals (AU:KAI) has released an update. Kairos Minerals Limited has announced a significant change in the holdings of its director, Dr. Pe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-director-acquires-85m-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-minerals-director-acquires-85m-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","BK4109","KAIR"],"gpt_icon":0},{"id":"2486815253","title":"Environmental Group And 2 Other ASX Penny Stocks To Boost Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2486815253","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486815253?lang=en_us&edition=fundamental","pubTime":"2024-11-28 07:06","pubTimestamp":1732748788,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the Australian market has remained flat, but it is up 18% over the past year with earnings forecast to grow by 13% annually. In light of these conditions, exploring stocks that combine growth potential with solid financial health can be a wise strategy. Penny stocks may be a somewhat outdated term, yet they continue to represent opportunities in smaller or newer companies that could offer growth at attractive price points.Click here to see the full list of 1,045 stocks from our ASX Penny Stocks screener.Assess Environmental Group's future earnings estimates with our detailed growth reports.Overview: Kairos Minerals Limited is a resource exploration company operating in Australia, with a market capit","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hHa1.rnFIozE8uk1FxFmIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7a92075e7c274cfc915511d1e9d413e3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hHa1.rnFIozE8uk1FxFmIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7a92075e7c274cfc915511d1e9d413e3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/environmental-group-2-other-asx-230628841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["KAIR","BK7055","BK7164","XAO.AU","BK7096","XKO.AU","SHA.AU","SRV.AU","BK7077","NGI.AU","BK7133","LBL.AU","BK7502","EVO.AU","BK7132","XJO.AU","MAY.AU","BK7131","HLO.AU","KAI.AU","BK7142","EGL.AU","ANG.AU","BK7088","BK7070","ATP.AU","BK7048","VLS.AU","BK7062","EZZ.AU","BK7095"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAIR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-01-03","symbol":"KAIR","reason":null,"defaultRemindTime":1672756200000,"announcedDate":"2022-12-09","type":"delisting","dateTimestamp":1672722000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAIR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAIR\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAIR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAIR","date":"2022-12-30","current":26.465036,"percent":0.788462,"low":-3152.741514,"twenty":-3123.993111,"median":-3101.633243,"eighty":41.121928,"high":58.491109,"avg":-1837.241689,"sd":1548.390193,"marketCap":347415000},"quantilePoints":[{"date":"2021-04-01","current":-3033.164824,"twenty":-3033.164824,"median":-3033.164824,"eighty":-3033.164824,"marketCap":327600000},{"date":"2021-04-09","current":-3146.35298,"twenty":-3133.575912,"median":-3122.395978,"eighty":-3108.021777,"marketCap":339825000},{"date":"2021-04-16","current":-3149.547247,"twenty":-3133.575912,"median":-3120.798845,"eighty":-3111.216044,"marketCap":340170000},{"date":"2021-04-23","current":-3146.35298,"twenty":-3146.35298,"median":-3131.978778,"eighty":-3111.216044,"marketCap":339825000},{"date":"2021-04-30","current":-3130.381645,"twenty":-3146.35298,"median":-3130.381645,"eighty":-3111.216044,"marketCap":338100000},{"date":"2021-05-07","current":-3123.993111,"twenty":-3146.35298,"median":-3130.381645,"eighty":-3114.410311,"marketCap":337410000},{"date":"2021-05-14","current":-3117.604578,"twenty":-3146.35298,"median":-3130.381645,"eighty":-3114.410311,"marketCap":336720000},{"date":"2021-05-21","current":-3096.841842,"twenty":-3146.35298,"median":-3130.381645,"eighty":-3110.577191,"marketCap":334477500},{"date":"2021-05-28","current":-3085.661908,"twenty":-3138.686739,"median":-3123.993111,"eighty":-3103.230376,"marketCap":333270000},{"date":"2021-06-04","current":-3111.216044,"twenty":-3135.492472,"median":-3120.798845,"eighty":-3103.230376,"marketCap":336030000},{"date":"2021-06-11","current":-3123.993111,"twenty":-3133.575912,"median":-3123.993111,"eighty":-3105.146936,"marketCap":337410000},{"date":"2021-06-18","current":-3111.216044,"twenty":-3133.575912,"median":-3120.798845,"eighty":-3103.230376,"marketCap":336030000},{"date":"2021-06-25","current":-3101.633243,"twenty":-3133.575912,"median":-3117.604578,"eighty":-3101.633243,"marketCap":334995000},{"date":"2021-07-02","current":-3101.633243,"twenty":-3133.575912,"median":-3117.604578,"eighty":-3101.633243,"marketCap":334995000},{"date":"2021-07-09","current":-3098.438976,"twenty":-3133.575912,"median":-3114.410311,"eighty":-3098.438976,"marketCap":334650000},{"date":"2021-07-16","current":-3101.633243,"twenty":-3133.575912,"median":-3111.216044,"eighty":-3098.438976,"marketCap":334995000},{"date":"2021-07-23","current":-3104.82751,"twenty":-3131.020498,"median":-3108.021777,"eighty":-3098.438976,"marketCap":335340000},{"date":"2021-07-30","current":-3098.438976,"twenty":-3130.381645,"median":-3108.021777,"eighty":-3098.438976,"marketCap":334650000},{"date":"2021-08-06","current":-3085.661908,"twenty":-3130.381645,"median":-3108.021777,"eighty":-3098.438976,"marketCap":333270000},{"date":"2021-08-13","current":-3104.82751,"twenty":-3130.381645,"median":-3108.021777,"eighty":-3098.438976,"marketCap":335340000},{"date":"2021-08-20","current":-3101.633243,"twenty":-3130.381645,"median":-3104.82751,"eighty":-3098.438976,"marketCap":334995000},{"date":"2021-08-27","current":-3098.438976,"twenty":-3129.103938,"median":-3104.82751,"eighty":-3098.438976,"marketCap":334650000},{"date":"2021-09-03","current":-3104.82751,"twenty":-3127.187378,"median":-3104.82751,"eighty":-3098.438976,"marketCap":335340000},{"date":"2021-09-10","current":-3108.021777,"twenty":-3127.187378,"median":-3104.82751,"eighty":-3098.438976,"marketCap":335685000},{"date":"2021-09-17","current":-3108.021777,"twenty":-3126.548525,"median":-3104.82751,"eighty":-3098.438976,"marketCap":335685000},{"date":"2021-09-24","current":-3109.61891,"twenty":-3123.993111,"median":-3104.82751,"eighty":-3098.438976,"marketCap":335857500},{"date":"2021-10-01","current":-3088.856175,"twenty":-3123.993111,"median":-3104.82751,"eighty":-3098.438976,"marketCap":333615000},{"date":"2021-10-08","current":-3127.187378,"twenty":-3123.993111,"median":-3108.021777,"eighty":-3098.438976,"marketCap":337755000},{"date":"2021-10-15","current":-3111.216044,"twenty":-3126.548525,"median":-3108.021777,"eighty":-3098.438976,"marketCap":336030000},{"date":"2021-10-22","current":-3120.798845,"twenty":-3123.993111,"median":-3108.021777,"eighty":-3098.438976,"marketCap":337065000},{"date":"2021-10-29","current":-3120.798845,"twenty":-3123.993111,"median":-3108.021777,"eighty":-3098.438976,"marketCap":337065000},{"date":"2021-11-05","current":-3117.604578,"twenty":-3123.993111,"median":-3108.021777,"eighty":-3098.438976,"marketCap":336720000},{"date":"2021-11-12","current":-3123.993111,"twenty":-3123.993111,"median":-3108.021777,"eighty":-3098.438976,"marketCap":337410000},{"date":"2021-11-19","current":-3120.798845,"twenty":-3123.993111,"median":-3108.021777,"eighty":-3098.438976,"marketCap":337065000},{"date":"2021-11-26","current":-3127.187378,"twenty":-3123.993111,"median":-3109.61891,"eighty":-3098.438976,"marketCap":337755000},{"date":"2021-12-03","current":-3127.187378,"twenty":-3127.187378,"median":-3111.216044,"eighty":-3098.438976,"marketCap":337755000},{"date":"2021-12-10","current":-3123.993111,"twenty":-3127.187378,"median":-3111.216044,"eighty":-3098.438976,"marketCap":337410000},{"date":"2021-12-17","current":-3123.993111,"twenty":-3127.187378,"median":-3111.216044,"eighty":-3098.438976,"marketCap":337410000},{"date":"2021-12-23","current":-3114.410311,"twenty":-3127.187378,"median":-3112.813178,"eighty":-3098.438976,"marketCap":336375000},{"date":"2021-12-31","current":-3127.187378,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3100.99439,"marketCap":337755000},{"date":"2022-01-07","current":-3127.187378,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":337755000},{"date":"2022-01-14","current":-3124.919449,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":337510050},{"date":"2022-01-21","current":-3111.216044,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":336030000},{"date":"2022-01-28","current":-3108.021777,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":335685000},{"date":"2022-02-04","current":-3119.201711,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":336892500},{"date":"2022-02-11","current":-3120.798845,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":337065000},{"date":"2022-02-18","current":-3117.604578,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":336720000},{"date":"2022-02-25","current":-3114.410311,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":336375000},{"date":"2022-03-04","current":-3120.798845,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":337065000},{"date":"2022-03-11","current":-3123.993111,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3102.272096,"marketCap":337410000},{"date":"2022-03-18","current":-3123.993111,"twenty":-3127.187378,"median":-3116.869896,"eighty":-3103.230376,"marketCap":337410000},{"date":"2022-03-25","current":-3114.410311,"twenty":-3127.187378,"median":-3117.604578,"eighty":-3103.86923,"marketCap":336375000},{"date":"2022-04-01","current":-3133.575912,"twenty":-3127.187378,"median":-3117.604578,"eighty":-3104.82751,"marketCap":338445000},{"date":"2022-04-08","current":41.172137,"twenty":-3127.187378,"median":-3117.604578,"eighty":-3101.633243,"marketCap":339480000},{"date":"2022-04-14","current":41.172137,"twenty":-3127.187378,"median":-3116.135215,"eighty":-3101.633243,"marketCap":339480000},{"date":"2022-04-22","current":41.213979,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3101.633243,"marketCap":339825000},{"date":"2022-04-29","current":41.255821,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3098.438976,"marketCap":340170000},{"date":"2022-05-06","current":41.172137,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3098.438976,"marketCap":339480000},{"date":"2022-05-13","current":41.004771,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3098.438976,"marketCap":338100000},{"date":"2022-05-20","current":57.959372,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3098.438976,"marketCap":338445000},{"date":"2022-05-27","current":58.018454,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3095.244709,"marketCap":338790000},{"date":"2022-06-03","current":58.107077,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3095.244709,"marketCap":339307500},{"date":"2022-06-10","current":58.166159,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3092.050442,"marketCap":339652500},{"date":"2022-06-17","current":58.077536,"twenty":-3127.187378,"median":-3114.410311,"eighty":-3085.661908,"marketCap":339135000},{"date":"2022-06-24","current":58.077536,"twenty":-3127.187378,"median":-3111.216044,"eighty":-3085.661908,"marketCap":339135000},{"date":"2022-07-01","current":58.077536,"twenty":-3125.373035,"median":-3111.216044,"eighty":-2418.330905,"marketCap":339135000},{"date":"2022-07-08","current":58.136618,"twenty":-3124.919449,"median":-3111.216044,"eighty":41.130296,"marketCap":339480000},{"date":"2022-07-15","current":58.1957,"twenty":-3124.382812,"median":-3111.216044,"eighty":41.130296,"marketCap":339825000},{"date":"2022-07-22","current":58.254781,"twenty":-3124.005888,"median":-3111.216044,"eighty":41.172137,"marketCap":340170000},{"date":"2022-07-29","current":58.491109,"twenty":-3123.993111,"median":-3109.61891,"eighty":41.172137,"marketCap":341550000},{"date":"2022-08-05","current":58.461568,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":341377500},{"date":"2022-08-19","current":22.59473,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":342240000},{"date":"2022-08-22","current":22.560564,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":341722500},{"date":"2022-08-31","current":22.571953,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":341895000},{"date":"2022-09-06","current":22.59473,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":342240000},{"date":"2022-09-16","current":22.640284,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":342930000},{"date":"2022-09-23","current":22.685838,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":343620000},{"date":"2022-09-30","current":22.663061,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":343275000},{"date":"2022-10-07","current":22.731391,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":344310000},{"date":"2022-10-14","current":22.731391,"twenty":-3123.993111,"median":-3108.021777,"eighty":41.172137,"marketCap":344310000},{"date":"2022-10-21","current":22.754168,"twenty":-3123.993111,"median":-3104.82751,"eighty":41.172137,"marketCap":344655000},{"date":"2022-10-28","current":22.776945,"twenty":-3123.993111,"median":-3104.82751,"eighty":41.172137,"marketCap":345000000},{"date":"2022-11-04","current":22.822499,"twenty":-3123.993111,"median":-3104.82751,"eighty":41.172137,"marketCap":345690000},{"date":"2022-11-10","current":22.822499,"twenty":-3123.993111,"median":-3104.82751,"eighty":41.172137,"marketCap":345690000},{"date":"2022-11-18","current":26.359912,"twenty":-3123.993111,"median":-3104.82751,"eighty":41.130296,"marketCap":346035000},{"date":"2022-11-25","current":26.386193,"twenty":-3123.993111,"median":-3104.82751,"eighty":41.130296,"marketCap":346380000},{"date":"2022-12-02","current":26.425615,"twenty":-3123.993111,"median":-3103.230376,"eighty":41.130296,"marketCap":346897500},{"date":"2022-12-09","current":26.412474,"twenty":-3123.993111,"median":-3101.633243,"eighty":41.130296,"marketCap":346725000},{"date":"2022-12-16","current":26.420096,"twenty":-3123.993111,"median":-3101.633243,"eighty":41.130296,"marketCap":346825050},{"date":"2022-12-23","current":26.438755,"twenty":-3123.993111,"median":-3101.633243,"eighty":41.130296,"marketCap":347070000},{"date":"2022-12-30","current":26.465036,"twenty":-3123.993111,"median":-3101.633243,"eighty":41.121928,"marketCap":347415000}],"updateTime":1746338580633}}}